Corporate Governance Biography

<< Back
Torsten Goesch

Torsten Goesch, MD, PhD, MBA

Board member

Dr. Torsten Goesch is a director of Rosetta Capital, formerly BioScience Managers Limited (BML) which he joined in July 2002. Previously, Dr. Goesch was the founder and Managing Director of TRG Invest (1999-2002), a Munich-based consulting business providing companies in the life science sector with support in strategic management, business development, technology management, mergers & acquisitions, new market entries and fundraising. Dr. Goesch has a proven commercial track record in building high-growth biotechnology and pharmaceutical companies, and is an experienced general manager in international business settings.

From 1997 to 1999, Dr. Goesch served as the General Manager for Central Europe for Biogen, which was, at the time, the second largest biotech company in the world. At Biogen, he built the Central-European business (Germany, Switzerland, and Austria) from start-up to DM100 million in sales within two years. Prior to Biogen, Dr. Goesch was based in London as the Commercial Head for the worldwide generics drug business of Merck Generics. He helped grow Merck Generics from US$100 million to US$400 million in sales and was actively involved in F. Merck’s Initial Public Offering. Merck Generics was one of the many acquisitions Dr. Goesch had managed in his previous role at Merck as Head of Strategy and Acquisitions (1993 to 1995).

From 1988 to 1990 Dr. Goesch practiced as a medical doctor in internal medicine at the University Hospital Hamburg-Eppendorf, with a particular focus on nephrology, immunology and oncology. Dr. Goesch received a MBA from the J.L. Kellogg Graduate School of Management at Northwestern University, Evanston, Chicago (1992) and holds a PhD (1988).